IT1277373B1 - Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato - Google Patents

Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Info

Publication number
IT1277373B1
IT1277373B1 IT95MI001649A ITMI951649A IT1277373B1 IT 1277373 B1 IT1277373 B1 IT 1277373B1 IT 95MI001649 A IT95MI001649 A IT 95MI001649A IT MI951649 A ITMI951649 A IT MI951649A IT 1277373 B1 IT1277373 B1 IT 1277373B1
Authority
IT
Italy
Prior art keywords
prevention
glutamate
purine
agonist
receptors
Prior art date
Application number
IT95MI001649A
Other languages
English (en)
Inventor
Cinzia Volonte
Daniela Merlo
Original Assignee
Consiglio Nazionale Ricerche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of ITMI951649A0 publication Critical patent/ITMI951649A0/it
Application filed by Consiglio Nazionale Ricerche filed Critical Consiglio Nazionale Ricerche
Priority to IT95MI001649A priority Critical patent/IT1277373B1/it
Priority to IL12291596A priority patent/IL122915A/xx
Priority to AT96927588T priority patent/ATE216878T1/de
Priority to AU67366/96A priority patent/AU707808B2/en
Priority to US09/000,403 priority patent/US6326370B1/en
Priority to BR9609856A priority patent/BR9609856A/pt
Priority to DK96927588T priority patent/DK0841907T3/da
Priority to CA002224293A priority patent/CA2224293A1/en
Priority to EP96927588A priority patent/EP0841907B1/en
Priority to PCT/EP1996/003254 priority patent/WO1997004760A1/en
Priority to JP9507214A priority patent/JPH11511126A/ja
Priority to RU98103500/14A priority patent/RU2211707C2/ru
Priority to DE69621022T priority patent/DE69621022T2/de
Priority to ES96927588T priority patent/ES2173307T3/es
Publication of ITMI951649A1 publication Critical patent/ITMI951649A1/it
Application granted granted Critical
Publication of IT1277373B1 publication Critical patent/IT1277373B1/it
Priority to HK99100850A priority patent/HK1015698A1/xx
Priority to US09/987,075 priority patent/US20020028790A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IT95MI001649A 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato IT1277373B1 (it)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
EP96927588A EP0841907B1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
JP9507214A JPH11511126A (ja) 1995-07-28 1996-07-24 グルタメートにより誘発される細胞毒性の防止のためのｐ▲下２▼プリノセプターの作動薬または拮抗薬の使用
AU67366/96A AU707808B2 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
US09/000,403 US6326370B1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of P2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
BR9609856A BR9609856A (pt) 1995-07-28 1996-07-24 Compostos agonistas ou antagonistas de purinoceptores P2 uso dos mesmos e composição farmacológica
DK96927588T DK0841907T3 (da) 1995-07-28 1996-07-24 Anvendelse af agonister eller antagonister for P2 purinreceptorer til forebyggelse af glutamatfremkaldt cytotoksicitet
CA002224293A CA2224293A1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
IL12291596A IL122915A (en) 1995-07-28 1996-07-24 Agonists and antagonists of p2 purinoceptor for use in the prevention of glutamate-evoked cytotoxicity and pharmaceutical compositions containing said agonist or antagonist
PCT/EP1996/003254 WO1997004760A1 (en) 1995-07-28 1996-07-24 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
AT96927588T ATE216878T1 (de) 1995-07-28 1996-07-24 Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet
RU98103500/14A RU2211707C2 (ru) 1995-07-28 1996-07-24 Применение агонистов или антагонистов p2-пуриноцепторов для предупреждения цитотоксичности, вызываемой глютаматом
DE69621022T DE69621022T2 (de) 1995-07-28 1996-07-24 Verwendung von agonisten oder antagonisten der p2 purinozeptoren zur vermeidung der durch glutamat bedingten zytotoxizitaet
ES96927588T ES2173307T3 (es) 1995-07-28 1996-07-24 Utilizacion de agonistas o antigonistas de los purinoreceptores p2 para la citotoxicidad provocada por el glutamato.
HK99100850A HK1015698A1 (en) 1995-07-28 1999-03-02 Use of agonists or antagonists of p2 purinoceptors for the prevention of glutamate-evoked cytotoxicity
US09/987,075 US20020028790A1 (en) 1995-07-28 2001-11-13 Use of agonists or antagonists of P2 purinoceptors for the prevention glutamate-evoked cytotoxicity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Publications (3)

Publication Number Publication Date
ITMI951649A0 ITMI951649A0 (it) 1995-07-27
ITMI951649A1 ITMI951649A1 (it) 1997-01-27
IT1277373B1 true IT1277373B1 (it) 1997-11-10

Family

ID=11372076

Family Applications (1)

Application Number Title Priority Date Filing Date
IT95MI001649A IT1277373B1 (it) 1995-07-28 1995-07-28 Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato

Country Status (15)

Country Link
US (2) US6326370B1 (it)
EP (1) EP0841907B1 (it)
JP (1) JPH11511126A (it)
AT (1) ATE216878T1 (it)
AU (1) AU707808B2 (it)
BR (1) BR9609856A (it)
CA (1) CA2224293A1 (it)
DE (1) DE69621022T2 (it)
DK (1) DK0841907T3 (it)
ES (1) ES2173307T3 (it)
HK (1) HK1015698A1 (it)
IL (1) IL122915A (it)
IT (1) IT1277373B1 (it)
RU (1) RU2211707C2 (it)
WO (1) WO1997004760A1 (it)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9615202D0 (en) * 1996-07-19 1996-09-04 Smithkline Beecham Plc Pharmaceuticals
SE9702002D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
US6462028B2 (en) * 1997-07-25 2002-10-08 Inspire Pharmaceuticals, Inc. Method of promoting cervical and vaginal secretions
IT1303815B1 (it) * 1998-12-02 2001-02-23 Consiglio Nazionale Ricerche Impiego di selettivi composti modulatori dei recettori purinici p2 perla prevenzione dei danni e della mortalita' causata da ischemia
US7141511B2 (en) * 2004-04-27 2006-11-28 Micron Technology Inc. Method and apparatus for fabricating a memory device with a dielectric etch stop layer
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
EP3323415A1 (en) * 2016-11-16 2018-05-23 Institut du Cerveau et de la Moelle Epiniere-ICM Treatment of neurodegenerative diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4230493A1 (de) 1992-09-11 1994-03-17 Institut Fuer Bioanalytik Gmbh Arzneimittel zur Behandlung des zentralen Nervensystems

Also Published As

Publication number Publication date
ATE216878T1 (de) 2002-05-15
ES2173307T3 (es) 2002-10-16
IL122915A (en) 2003-05-29
DE69621022T2 (de) 2003-02-27
DK0841907T3 (da) 2002-07-15
CA2224293A1 (en) 1997-02-13
HK1015698A1 (en) 1999-10-22
EP0841907A1 (en) 1998-05-20
AU707808B2 (en) 1999-07-22
ITMI951649A1 (it) 1997-01-27
DE69621022D1 (de) 2002-06-06
RU2211707C2 (ru) 2003-09-10
BR9609856A (pt) 1999-03-16
ITMI951649A0 (it) 1995-07-27
WO1997004760A1 (en) 1997-02-13
IL122915A0 (en) 1998-08-16
JPH11511126A (ja) 1999-09-28
US20020028790A1 (en) 2002-03-07
US6326370B1 (en) 2001-12-04
EP0841907B1 (en) 2002-05-02
AU6736696A (en) 1997-02-26

Similar Documents

Publication Publication Date Title
EP0550631A4 (en) Compounds having antihypertensive and anti-ischemic properties
AU7622500A (en) High affinity small molecule c5a receptor modulators
PA8484201A1 (es) Derivados de adenina
HUT73807A (en) 5-ht1-like indole derivatives and pharmaceutical compositions containing them
TW217407B (it)
ES2175350T3 (es) Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso.
HUP0100495A2 (en) Use of prostaglandin (pge2)receptor 4 (ep4)selective agonists for producing pharmaceutical compositions suitable for the treatment of acute and chronic renal failure
WO2000008015A3 (en) Fsh mimetics for the treatment of infertility
HUP0104696A2 (hu) 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére
IT1277373B1 (it) Impiego di composti agonisti o antagonisti dei recettori purinici p2 per la prevenzione della citotossicita' da glutammato
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
WO2001083693A8 (en) Compounds having affinity for the vascular endothelial growth factor receptor-2 (vegfr-2) and associated uses
EA200100089A1 (ru) Предотвращение рецидива мигрени
NO992298L (no) Konformasjonsbegrensede LH-RH analoger, anvendelse derav og farmas°ytiske sammensetninger inneholdende disse
MXPA04000023A (es) Derivados de acido cicloalquilpirrol-3-carboxilico y derivados de acido heterocicloalquilpirrol-3-carboxilico como ligandos de receptor gabaa.
WO1999052936A3 (en) Arginine peptide analogs useful as fibroblast growth factor antagonists
ES2173027A2 (es) Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.
ECSP972049A (es) Derivados de lactama

Legal Events

Date Code Title Description
0001 Granted